SLC45A4's effect on GABA levels in cells
Investigating the Role of SLC45A4 in GABA Metabolism
This work looks at whether the protein SLC45A4 controls GABA levels in non‑nerve cells, which could influence cancer cell behavior and other health conditions.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project ID | NIH-11261032 on NIH RePORTER |
What this research studies
Researchers combine computer analysis of public gene expression and metabolite datasets to find links between SLC45A4 and cellular GABA levels. They follow up those links with lab experiments in human cancer and other non‑neuronal cell models. Using stable isotope tracing and biochemical assays, they trace whether SLC45A4 changes GABA production, breakdown, or transport rather than just uptake. The goal is to define the molecular role of this previously uncharacterized transporter and point toward possible future targets for therapy.
Who could benefit from this research
Good fit: Patients who might be eligible are those willing to provide tissue, biospecimens, or clinical data for studies of GABA metabolism in cancers or related observational efforts tied to the project.
Not a fit: People seeking an immediate new treatment are unlikely to benefit because this is laboratory mechanistic research rather than a clinical trial.
Why it matters
Potential benefit: If successful, this work could reveal a new mechanism controlling GABA in non‑neuronal cells and identify SLC45A4 as a potential drug target for cancers or other conditions involving GABA signaling.
How similar studies have performed: Other SLC transporters have been linked to human disease and drug action, but SLC45A4's specific role in GABA metabolism is a novel finding now being tested with mechanistic experiments.
Where this research is happening
Newark, UNITED STATES
- Rutgers Biomedical and Health Sciences — Newark, United States (Active)
Researchers
- Principal investigator: Su, Xiaoyang — Rutgers Biomedical and Health Sciences
- Study coordinator: Su, Xiaoyang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.